

## Community Health Network Oncology Research - Enrolling Clinical Trials

6/9/2025

Multiple Disease Sites		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab	NCT05005403	ABBV-514 is a T-reg cell depleter	NSCLC, HNSCC	NA	Indy
Amgen 20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors	NCT05094336	PRMT5 Inhibitor	Advanced MTAP-null Solid Tumors Dose Expansion: NSCLC, Squamous Esophageal/Gastric, Non-Squamous Esophageal	MTAP-null	North and East
Artios ART0380C001	A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors	NCT04657068	ART0380	Advanced or metastatic solid tumors w/ATM alterations	ATM	North
Boehringer Ingelheim 1479-0009	Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour	NCT06581432	BI 1810631	HER2-mutated or overexpressed/amplified solid tumours		North & East (South Pending)
C4 Therapeutics CFT1946-1101	A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination therapy in Subjects with BRAF-V600 Mutant Solid Tumors	NCT05668585	CFT1946	BRAF-V600 Mutant Solid non-CNS Tumors	BRAF-V600	Indy
Endeavor ENV-ONC-501	A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients with Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors	NCT06956690	ENV-501	Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors		North Only
GV20 Therapeutics GV20-0251-100	An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Advanced and/or Refractory Solid Tumor Malignancies	IGSF8 and others	North and South
KaliVir STEALTH-001	A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors	NCT06444815	VET3-TGI	Advanced Solid Tumors IV Cohort Only	Various	Indy

Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors	KRAS G12D	Indy
Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS C12C-Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	NSCLC, Pancreatic	KRAS G12C	Indy
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	Various	Various	Indy
Relay Therapeutics RLY-2608-101	Relay Therapeutics RLY-2608-101, A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer	NCT05216432	RLY-2608	Unresectable or metastatic solid tumors	PIK3CA	North and South
Servier CL1-95035-001	A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP	NCT06188702	MAT2A inhibitor	Advanced or metastatic solid tumors	MTAP	North (South & East Pending)
Tempus TP-CA-005	Polaris - Umbrella Study for Analysis of Data Related to Patients with Cancer	NCT06018753	N/A - data collection only	Subjects diagnosed with cancer	N/A	Indy

Breast		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
BioNTech BNT327-02	A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer	NCT06449222	BNT327	TNBC	PD-L1, HR (ER and PR), and HER2	Indy
CCTG MA.39	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer	NCT03488693	RT	Low-risk breast cancer (Oncotype DX ≤25) or T3N0 disease	ER+	Indy
Relay Therapeutics RLY-2608-101	A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer	NCT05216432	RLY-2608	HR+, HER2– locally advanced or metastatic breast cancer	PIK3CA HR+, HER2–	North and South

Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Expansion - TNBC	KIF18A	North and South
---------------------------	--	-------------	-----------------------	------------------	--------	-----------------

Lung		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab	NCT05005403	ABBV-514 is a T-reg cell depleter	NSCLC	NA	Indy
Amgen 20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors	NCT05094336	PRMT5 Inhibitor	Advanced MTAP-null Solid Tumors Dose Expansion: NSCLC	MTAP-null	North and East
C4 Therapeutics CFT1946-1101	A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination therapy in Subjects with BRAF V600 Mutant Solid Tumors	NCT05668585	CFT1946	BRAF-V600 Mutant NSCLC	BRAF-V600	Indy
Genmab GCT1046-06	A Phase 3 Trial of an IO-bispecific antibody in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy	NCT06635824	PD-L1×4-1BB bispecific antibody	PD-L1 Positive Metastatic NSCLC	PD-L1 and various	Indy
Lilly J3M-MC-JZQB	SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression	NCT06119581	LY3537982 in combination with Pembrolizumab Pemetrexed and Platinum	KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC	KRAS G12C-Mutant	North and South
Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors NSCLC	KRAS G12D	Indy
Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS C12C-Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	NSCLC	KRAS G12C	Indy
Seagen SGNB6A-001	A Phase 1 Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	ADC targeting integrin beta-6	Dose expansion NSCLC	Integrin beta-6	Indy

SignalChem SLC-391-102	A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (SKYLITE)	NCT05860296	Selective AXL Inhibitor	NSCLC ICI Naïve & ICI Resistant	AXL/TYR03/MER	North and South
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Expansion - sq-NSCLC	KIF18A	North and South

Hematology		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	Multiple Myeloma, B cell NHL	Various	Indy
CellCentric CCS1477	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies	NCT04068597	CCS1477	MM	Various	Indy
Pfizer C1071032	MAGNETISMM-32: A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Bortezomib, Dexamethasone (Pvd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy	NCT06152575	BsABS against BCMA and CD3	Relapsed/Refractory Multiple Myeloma	Various	North for C1D1 & C1D4 (if C1D1 is not tolerated well); open @ South for all other cycles

Head and Neck		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab	NCT05005403	ABBV-514 is a T-reg cell depleter	HNSCC	NA	Indy
Amgen 20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors	NCT05094336	PRMT5 Inhibitor	Advanced MTAP-null Solid Tumors Dose Expansion: 1f: HNSCC	MTAP-null	North and East
C4 Therapeutics CFT1946-1101	A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination therapy in Subjects with BRAF-V600 Mutant Solid Tumors	NCT05668585	CFT1946	BRAF-V600 Mutant Anaplastic thyroid carcinoma	BRAF-V600	Indy
GV20 Therapeutics GV20-0251-100	An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Squamous head and neck	IGSF8 and others	North and South

MDA 2020-1153	A randomized study of head and neck radiotherapy with or without customized 3D printed oral stents	NCT04870762	Head and Neck Radiotherapy	Head and Neck Cancers	NA	Indy (Pts must start at North for scan)
Seagen SGNB6A-001	A Phase 1 Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	ADC targeting integrin beta-6	Dose expansion HNSCC	Integrin beta-6	Indy

Gyn		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
GV20 Therapeutics GV20-0251-100	GV20-0251-100, An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Endometrial carcinoma	IGSF8 and others	North and South
Kelun SKB264-II-06	A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination with Pembrolizumab in Subjects with Selected Solid Tumors	NCT05642780	TROP2 monoclonal antibody (mAb) of immunoglobulin (Ig)G1 class & toxin molecule KL610023	2L or 3L recurrent or metastatic cervical cancer	TROP2	North
Volastra VLS-1488-2201	A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer	NCT05902988	Oral KIF18A Inhibitor	Expansion - HGSOC	KIF18A	North and South
Zentalis ZN-c3-005 GOG-3066	A Phase 2 Open-Label, Multicenter, Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (DENALI)	NCT05128825	WEE-1 Inhibitor	Part 1b: high cyclin E1 protein expression (regardless of CCNE1 gene amp status); Part 2: <i>Cohort 2A</i> CCNE1 gene amplified, <i>Cohort 2B</i> CCNE1 non-amplified/cyclin E1 IHC-Positive, <i>Cohort 2C</i> CCNE1 non-amplified/cyclin E1 IHC-Low/Negative	CCNE1 amplification, cyclin E1 protein expression	Indy

Genitourinary		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
Gastrointestinal		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
AbbVie M21-410	A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab	NCT05005403	ABBV-514 is a T-reg cell depleter	Panc, Gastric/GEJ	NA	Indy

AbbVie M24-064	An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	NCT06614192	ABBV-400 / ADC	c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	c-Met	Indy
AbbVie M24-311	A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer	NCT06107413	c-Met targeting antibody conjugated to a potent inhibitor of Top1 payload	CRC	c-Met	North & South (East Pending)
Amgen 20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors	NCT05094336	PRMT5 Inhibitor	Advanced MTAP-null Solid Tumors Dose Expansion: 1e: BTC; 1g: PDAC	MTAP-null	North and East
Artios ART0380C001	A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors	NCT04657068	ART0380	Advanced or metastatic solid tumors w/ATM alterations  Colorectal	ATM	North
C4 Therapeutics CFT1946-1101	A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination therapy in Subjects with BRAF-V600 Mutant Solid Tumors	NCT05668585	CFT1946	BRAF-V600 Mutant mCRC	BRAF-V600	Indy
CG Pharma CG-745-2-08	A Phase 1b/2, Dose-escalation, Randomized, Multicenter study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy	NCT05249101	pan-HDAC inhibitor	Metastatic Pancreatic enrolling in Phase 2 (Ivaltinostat 250 mg/m2)	NA	Indy
Janssen 89402638GIC1001	A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer	NCT06663319	ADC	Unresectable Metastatic CRC	GUCY2C	North Only (South & East Pending)
Lilly J5J-OX-JZZA	Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor	NCT06586515	LY3962673	KRAS G12D-Mutant Solid Tumors  CRC, PDAC	KRAS G12D	Indy

Lilly/LOXO LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients with KRAS G12C Mutant Advanced Solid Tumors	NCT04956640	KRAS G12C Inhibitor	Pancreatic, CRC	KRAS G12C	Indy
MDA TAPUR	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	NCT02693535	Various	CRC - Nivo and Ipi cohort (BRCA1 and BRCA2 mutation)	Various	Indy

Melanoma		NCT #	Study Drug MOA	Indication/Population	Biomarker Target	Sites Open
GV20 Therapeutics GV20-0251-100	GV20-0251-100, An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies	NCT05669430	IGSF8 antibody	Cutaneous melanoma	IGSF8 and others	North and South
C4 Therapeutics CFT1946-1101	A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination therapy in Subjects with BRAF-V600 Mutant Solid Tumors	NCT05668585	CFT1946	BRAF-V600 Mutant Melanoma (enrolling in Arm A 640mg BID Exploratory Expansion)	BRAF-V600	Indy